Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Gossamer Bio, Inc. (GOSS)

New York, New York--(Newsfile Corp. - March 3, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension. The Company had publicly characterized the PROSERA patient population as well-suite ...